Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoHealth (GOCO) EBITDA (2019 - 2025)

GoHealth's EBITDA history spans 7 years, with the latest figure at -$287.9 million for Q3 2025.

  • For Q3 2025, EBITDA fell 574.72% year-over-year to -$287.9 million; the TTM value through Sep 2025 reached -$300.4 million, down 315.71%, while the annual FY2024 figure was -$7.0 million, 91.37% up from the prior year.
  • EBITDA for Q3 2025 was -$287.9 million at GoHealth, down from -$99.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $80.3 million in Q4 2024 and bottomed at -$423.2 million in Q4 2021.
  • The 5-year median for EBITDA is -$40.6 million (2024), against an average of -$67.2 million.
  • The largest annual shift saw EBITDA crashed 5416.28% in 2021 before it soared 432.98% in 2024.
  • A 5-year view of EBITDA shows it stood at -$423.2 million in 2021, then soared by 68.53% to -$133.2 million in 2022, then surged by 111.31% to $15.1 million in 2023, then skyrocketed by 432.98% to $80.3 million in 2024, then crashed by 458.7% to -$287.9 million in 2025.
  • Per Business Quant, the three most recent readings for GOCO's EBITDA are -$287.9 million (Q3 2025), -$99.4 million (Q2 2025), and $6.7 million (Q1 2025).